Denali Therapeutics Inc. DNLI Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Denali Therapeutics Inc. (DNLI) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $566K in Q1 2026.
- How has Denali Therapeutics Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Denali Therapeutics Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 1517.1% year-over-year, from $35K to $566K.
- What is the long-term trend for Denali Therapeutics Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -4.4% compound annual growth rate (CAGR), from $25K to $20K.